Med BioGene Completes Final Tranche of Financing
August 18, 2008 Dear Shareholder: I would like to draw to your attention last week's news release (click here) where Med BioGene (MBI-TSX Venture Exchange www.medbiogene.com) announced that it had completed the second and final tranche of its previously announced public offering by way of short form prospectus through the issuance of 1,469,000 units (the “Units”) at a price of $0.15 per unit for gross proceeds of approximately $220,000. The first tranche of the Offering closed on August 7, 2008 and resulted in gross proceeds of approximately $1.6 million. MBI's principal business objective that we intend to accomplish with the net proceeds from the offering is to begin in 2009 commercialization in the United States of LungExpress Dx™. We expect to commercialize LungExpress Dx™ first in the United States and then in other jurisdictions as is prudent by (a) entering into a strategic partnership with an established diagnostics company or companies (which we expect would occur in advance of commercialization) with a clinical laboratory that is accredited under the Clinical Laboratory Improvement Amendments of 1988 ("CLIA") and by the College of American Pathologists ("CAP"), along with an established marketing and commercialization team, or (b) establishing our own laboratory, registered or accredited under CLIA and CAP, along with our own marketing and commercialization team. We are pleased with the support that we have received to allow us to close our public offering in extremely difficult financial markets. We look forward to executing upon our commercialization strategy and creating shareholder value. Thanks for your interest and support. Please call me if you have any questions or wish to discuss. Erinn B. Broshko
Chief Executive Officer
(604) 306-4969
ebroshko@medbiogene.com
www.medbiogene.com For investor relations information, please contact:
Certain statements made herein contain forward-looking information under applicable Canadian securities legislation. It is strongly suggested that you read our legal disclaimer by clicking here. | 
Home 
